Genfit S.A. (GNFT) NASDAQ
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Genfit S.A.
Sector
Healthcare
Industry
Biotechnology
Employees
180
First IPO Date
March 27, 2019
Key Executives
| Name | Title | Pay | Year Born |
| Pascal Prigent | Chief Executive Officer | 718,470 | 1968 |
| Jean-Francois Mouney | Co-Founder & Chairman of the Board | 441,579 | 1955 |
| Sakina Sayah-Jeanne | Chief Scientific Officer | 798,270 | 1972 |
| Laurent Lannoo | Corporate Secretary & Director of Legal Affairs | 0 | 1970 |
| Pascal Caisey | Chief Operating Officer | 0 | 1968 |
| Thomas Baetz | Chief Financial Officer | 0 | 1974 |
| Emilie Desodt | Executive Vice President of Human Resources | 0 | 1983 |
| Stefanie Magner | Chief Compliance Officer & Executive Vice President of International Legal Affairs | 0 | 1981 |
| Bart Staels | Co-Founder & Chairman of the Scientific Advisory Board | 0 | 1963 |
| Jean-Christophe Marcoux | Chief Corporate Affairs Officer, Head of Investor Relations & Head of ESG | 0 | 1977 |
Description
Genfit S.A. operates as a biopharmaceutical company dedicated to discovering and advancing novel therapeutic candidates and diagnostic solutions for a range of metabolic and liver-related diseases. Its most advanced drug candidate, Elafibranor, is currently undergoing Phase 3 clinical evaluation for the treatment of primary biliary cholangitis (PBC). Beyond therapeutics, Genfit is also developing its NIS4 technology, designed to aid in the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis. The company's pipeline further encompasses GNS561, which is in Phase 1b/2 trials for cholangiocarcinoma (CCA), and Nitazoxanide, undergoing Phase 1 evaluation as a potential therapy for acute-on-chronic liver failure. Genfit has established strategic partnerships, including a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test. Additionally, it collaborates with Genoscience Pharma to jointly develop and market the investigational treatment GNS561 for CCA. Founded in 1999, Genfit S.A. is headquartered in Loos, France.
